Table 3

Frequencies of previously detected genetic variants for RA: comparison of meta-analysis of ACPA-positive RA patients from three populations with ACPA-negative RA patients

EIRA ACPA-positiveEIRA ACPA-negativeNARACWTCCCACPA-positive RAACPA-negative RA
SNPChromosomeGene/lociMinor allele*MAF casesMAF controlsMAF casesMAF controlsMAF casesMAF controlsMAF casesMAF controlsOR (95%CI)*OR (95%CI)
rs38907451p36MMEL1-TNFRSF14C0.280.310.290.310.290.320.290.340.85 (0.80 to 0.91)0.94 (0.82 to 1.09)
rs24766011p13PTPN22A0.180.120.140.120.160.080.150.091.74 (1.59 to 1.90)1.17 (0.96 to 1.42)
rs75748652q32STAT4T0.240.220.260.220.250.230.230.211.12 (1.05 to 1.21)1.23 (1.05 to 1.43)
rs30872432q33CTLA4A0.340.390.380.390.380.420.430.450.88 (0.83 to 0.93)0.97 (0.84 to 1.11)
rs20644766p21HLA-DPB1G0.200.260.270.260.220.300.250.310.71 (0.66 to 0.76)1.02 (0.88 to 1.18)
rs104991946q23OLIG3,TNFAIP3T0.190.210.200.210.250.300.250.270.86 (0.80 to 0.92)1.28 (1.10 to 1.50)
rs69202206q23OLIG3,TNFAIP3A0.250.230.240.230.240.190.260.221.22 (1.14 to 1.31)1.08 (0.93 to 1.26)
rs38073067q32IRF5G0.450.490.410.490.480.500.460.500.87 (0.81 to 0.92)0.72 (0.63 to 0.82)
rs28123789p13CCL21G0.350.320.360.320.350.330.370.341.14 (1.07 to 1.21)1.21 (1.05 to 1.39)
rs37618479q33TRAF1-C5G0.510.460.480.460.470.380.430.431.32 (1.21 to 1.44)1.08 (0.95 to 1.23)
rs475031610p15PRKCQC0.170.210.190.210.180.190.160.200.83 (0.77 to 0.90)0.87 (0.74 to 1.03)
rs167854212q13KIF5A-PIP4K2CG0.400.420.420.420.360.370.330.370.88 (0.82 to 0.93)0.99 (0.87 to 1.14)
rs132867413q14-q21HTR2AT0.040.020.040.020.040.040.040.041.16 (0.99 to 1.35)1.83 (1.25 to 2.68)
rs481048520q13CD40T0.200.240.240.240.210.270.230.240.77 (0.69 to 0.85)0.98 (0.84 to 1.14)
  • Statistically significant odds ratios shown in bold.

  • * Mantel–Haenszel OR from meta-analysis of EIRA ACPA-positive RA/NARAC/WTCCC.

  • Mantel–Haenszel OR for EIRA ACPA-negative RA.

  • WTCCC excluded due to heterogeneity between ACPA positive cohorts.

  • ACPA, antibodies to citrullinated peptide antigens; EIRA, Swedish Epidemiological Investigation of Rheumatoid Arthritis; MAF, minor allele frequency; NARAC, North American RA Consortium; RA, rheumatoid arthritis; SNP, single nucleotide polymorphism; WTCCC, Wellcome Trust Case–Control Consortium.